


Taselisib

Chemical Properties

CAS No. :	1282512-48-4
Formula:	C ₂₄ H ₂₈ N ₈ O ₂
Molecular Weight:	460.53
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Taselisib (GDC-0032) is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity.
Targets(IC50)	Carbonic Anhydrase,PI3K
In vitro	Combination of GDC-0032 with fulvestrant, which enhanced fulvestrant activity, resulted in tumor regression and delayed tumor growth (91% tumor growth inhibition (TGI)). In addition, the combination of GDC-0032 with tamoxifen enhanced the potency of tamoxifen in vivo, and the tumor growth inhibition rate of GDC-0032 was 102%. The pharmacokinetics of GDC-0032 were approximately dose proportional and time independent, with a mean t _{1/2} of 40 hours.
In vivo	Preclinical data indicate that GDC-0032 has increased activity in PI3K α isoform (PIK3CA) mutant and HER2-expanded cancer cell lines.GDC-0032 inhibits MCF7-neo/HER2 cell proliferation with an IC ₅₀ of 2.5 nM.GDC-0032 is an orally bioavailable, potent, and selective inhibitor of class I PI3K α , δ , and γ isoforms. GDC-0032 is an orally bioavailable, potent and selective inhibitor of class I PI3K α , δ and γ isoforms, with a 30-fold lower inhibition of PI3K β isoforms compared to PI3K α isoforms.
Kinase Assay	Characterization of Biochemical and Cellular Activity in Vitro: Enzymatic activity of the class I PI3K isoforms is measured using a fluorescence polarization assay that monitors formation of the product 3,4,5-inositoltriphosphate molecule as it competes with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidyl inositide-3-phosphate product results in a decrease in fluorescence polarization signal as the labeled fluorophore is displaced from the GRP-1 protein binding site. Class I PI3K isoforms are expressed and purified as heterodimeric recombinant proteins. Tetramethylrhodamine-labeled PIP3 (TAMRA-PIP3), di-C8-PIP2, and PIP3 detection reagents are purchased from Echelon Biosciences. PI3K α is assayed under initial rate conditions in the presence of 10 mM Tris (pH 7.5), 25 μ M ATP, 9.75 μ M PIP2, 5% glycerol, 4 mM MgCl ₂ , 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 2% (v/v) DMSO at 60 ng/mL. After assay for 30 min at 25 °C, reactions are terminated with a final concentration of 9 mM EDTA, 4.5 nM TAMRA-PIP3, and 4.2 μ g/mL GRP-1 detector protein before reading fluorescence polarization on an Envision plate reader. IC ₅₀ values are calculated from the fit of the dose-response curves to a 4-parameter equation. Each reported value is an average of three experiments, and all have a standard deviation less than one geometric mean.

A DRUG SCREENING EXPERT

Cell Research	GDC-0032 is dissolved in DMSO. Cells are seeded in replicates of 6 in 96-well plates with 500 to 5,000 cells/well overnight and then treated with GDC-0032. After 4 days, the media are removed and the cells are fixed with 4% glutaraldehyde for 30 minutes. Fixed cells are stained with 0.1% crystal violet for 2 minutes, then washed, and dissolved in 10% acetic acid.
---------------	---

Solubility Information

Solubility	DMSO: 62.5 mg/mL (135.71 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 6.25 mg/mL (13.57 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.34 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1714 mL	10.8571 mL	21.7141 mL
5 mM	0.4343 mL	2.1714 mL	4.3428 mL
10 mM	0.2171 mL	1.0857 mL	2.1714 mL
50 mM	0.0434 mL	0.2171 mL	0.4343 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ndubaku CO, et al. J Med Chem, 2013, 56(11), 4597-4610.

Huang Q, Ru Y, Luo Y, et al. Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases. Science Advances. 2024, 10(13): eadk1200.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481